Therapnea Labs

Company Overview

Snapshot

Founded in January 2013 by Avi Lior and Noam Hadas, Therapnea Labs is an early-stage MedTech company with 1–10 employees. The company has raised $56K across one funding round and is developing a novel, patented technology to treat Obstructive Sleep Apnea.

Business overview

Therapnea Labs is a MedTech company focused on developing a patented technology to treat Obstructive Sleep Apnea (OSA). Its core product is a stent, applied inside the patient's mouth from a dental plate, designed to provide mechanical support for upper airways and prevent airway collapse. The company has developed a method to circumvent the gag reflex, which has historically hindered this approach. Therapnea Labs serves the healthcare and life sciences sectors, targeting patients with sleep disorders in geomarkets including Europe, China, and the United States.

Company Intelligence Q&A

What is Therapnea Labs' core technology?

Therapnea Labs has developed a novel, patented technology involving a stent applied inside the patient's mouth from a dental plate. This stent provides mechanical support for the upper airways to prevent airway collapse, specifically designed to circumvent the gag reflex.

When was Therapnea Labs founded and by whom?

Therapnea Labs was founded in January 2013 by co-founders Avi Lior and Noam Hadas.

What markets does Therapnea Labs target?

Therapnea Labs targets geomarkets including Europe, China, and the United States for its medical device solutions.

What is the primary medical condition Therapnea Labs aims to address?

Therapnea Labs is focused on treating Obstructive Sleep Apnea (OSA), a condition often referred to as 'the silent killer'.

What is the current product development stage for Therapnea Labs?

Therapnea Labs' product is currently in the clinical trial stage, with a proof-of-concept study showing promising results in circumventing nausea and the gag reflex while preventing apnea events.